Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
DuPont Liveo continued investments demonstrate our long-term commitment to the healthcare industry
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
The collaboration between CORONA and Ferring will cater to patients across India
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
Subscribe To Our Newsletter & Stay Updated
